Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment
As part of the initial collaboration,
The initial aim of this collaboration is to better identify and monitor patients who may benefit from existing ALK-based therapies as well as those that may benefit from second-generation therapies based on inhibitor resistance mechanisms.
"As the field of ALK-based therapies continues to grow with second- and third-generation molecules, the concept of looking at both DNA and RNA from CTCs is a diagnostic approach Insight has been interested in exploring for some time.
"The ability to obtain information about a tumor through a simple, blood-based test is appealing in that it can not only qualify patients for targeted therapies, but also aid in the monitoring of these patients for changes in a tumor as disease progresses," Morris added. "By combining our existing expertise in ALK testing with
ALK is incorporated into the testing guidelines utilized by oncologists when making treatment decisions in NSCLC patients. ALK positive patients now have targeted treatment options with two key drugs that have been approved by the
About Insight Genetics
Insight Genetics is dedicated to improving the lives of cancer patients through advanced molecular diagnostics that enable precision in cancer care. The company specializes in the discovery, development and commercialization of companion diagnostics that detect specific cancer biomarkers and assist in guiding the effective diagnosis and treatment of cancer. Insight Genetics is an ISO 9001:2008 and
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although
CONTACT: Investor Contact:
The Ruth Group David Burke(646) 536-7009 email@example.com Media Contact: The Ruth Group Melanie Sollid-Penton(646) 536-7023 firstname.lastname@example.org
News Provided by Acquire Media